GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jointown Pharmaceutical Group Co 600998.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

5.19

-0.95%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥161.39bn

FY2016FY2025

Net income

CN¥2.25bn

FY2016FY2025

Free cash flow

CN¥2.04bn

FY2016FY2025

Shareholders' equity

CN¥28.55bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥161.39bnCN¥151.81bnCN¥150.14bnCN¥140.42bnCN¥122.41bnCN¥110.86bnCN¥99.50bnCN¥87.14bnCN¥73.94bnCN¥61.56bn
Gross profitCN¥12.55bnCN¥11.74bnCN¥12.00bnCN¥10.86bnCN¥9.77bnCN¥9.88bnCN¥8.67bnCN¥7.49bnCN¥6.21bnCN¥4.80bn
Research and developmentCN¥128.8mCN¥146.7mCN¥196.6mCN¥178.4mCN¥194.9mCN¥126.6mCN¥74.1mCN¥76.2mCN¥73.1mCN¥56.4m
Operating incomeCN¥4.04bnCN¥3.92bnCN¥3.02bnCN¥2.85bnCN¥3.59bnCN¥4.35bnCN¥3.22bnCN¥2.53bnCN¥1.94bnCN¥1.70bn
Net incomeCN¥2.25bnCN¥2.51bnCN¥2.17bnCN¥2.08bnCN¥2.45bnCN¥3.08bnCN¥1.73bnCN¥1.34bnCN¥1.45bnCN¥876.7m
Diluted earnings per share0.450.490.430.390.450.580.250.260.290.20

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥116.41bnCN¥102.40bnCN¥92.79bnCN¥92.27bnCN¥85.94bnCN¥80.82bnCN¥71.15bnCN¥66.67bnCN¥52.05bnCN¥38.73bn
Cash and short-term investments—CN¥18.36bnCN¥17.04bnCN¥17.50bnCN¥18.30bnCN¥14.82bnCN¥12.17bnCN¥12.70bnCN¥8.54bnCN¥5.24bn
Total liabilitiesCN¥79.54bnCN¥68.80bnCN¥63.31bnCN¥63.59bnCN¥58.86bnCN¥55.21bnCN¥49.18bnCN¥46.29bnCN¥32.51bnCN¥26.72bn
DebtCN¥1.64bnCN¥11.65bnCN¥12.63bnCN¥15.20bnCN¥16.98bnCN¥17.69bnCN¥14.55bnCN¥11.88bnCN¥8.50bnCN¥6.82bn
Shareholders' equityCN¥28.55bnCN¥27.24bnCN¥23.98bnCN¥24.64bnCN¥23.41bnCN¥21.83bnCN¥18.75bnCN¥18.47bnCN¥18.30bnCN¥11.28bn
Shares outstanding5,042m5,093m5,026m5,396m5,464m5,347m6,913m5,214m5,010m4,293m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥3.44bnCN¥3.08bnCN¥4.78bnCN¥3.99bnCN¥3.46bnCN¥3.44bnCN¥2.77bnCN¥1.22bn−CN¥1.01bnCN¥431.3m
Capital spending−CN¥1.40bn−CN¥975.4m−CN¥1.05bn−CN¥1.24bn−CN¥1.39bn−CN¥1.46bn−CN¥1.19bn−CN¥1.81bn−CN¥1.09bn−CN¥1.15bn
Free cash flowCN¥2.04bnCN¥2.11bnCN¥3.73bnCN¥2.74bnCN¥2.07bnCN¥1.99bnCN¥1.58bn−CN¥592.8m−CN¥2.10bn−CN¥719.2m
Dividends paid−CN¥1.48bn−CN¥1.55bn−CN¥936.9m−CN¥548.6m−CN¥914.4m−CN¥737.7m−CN¥187.4m−CN¥967.1m−CN¥709.5m−CN¥723.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥42.50bnCN¥44.78bnCN¥42.06bnCN¥38.22bnCN¥39.09bnCN¥42.02bnCN¥38.38bnCN¥36.26bn
Gross profitCN¥3.44bnCN¥3.34bnCN¥3.29bnCN¥3.13bnCN¥2.96bnCN¥3.08bnCN¥2.70bnCN¥2.96bn
Operating incomeCN¥1.07bnCN¥1.20bnCN¥956.0mCN¥908.4mCN¥921.6mCN¥914.1mCN¥759.3mCN¥630.9m
Net incomeCN¥467.4mCN¥733.2mCN¥279.4mCN¥529.9mCN¥475.7mCN¥969.9mCN¥811.2mCN¥488.5m
Diluted earnings per share0.090.150.060.110.090.190.160.10
Cash from operations———CN¥528.0mCN¥507.0m−CN¥3.27bn—CN¥547.0m
Capital spending−CN¥255.0m−CN¥340.0m−CN¥335.0m−CN¥281.0m−CN¥355.0m−CN¥429.0m−CN¥304.0m−CN¥238.0m
Free cash flow———CN¥247.0mCN¥152.0m−CN¥3.70bn—CN¥309.0m
Total assetsCN¥120.78bnCN¥121.72bnCN¥116.41bnCN¥112.28bnCN¥107.77bnCN¥108.88bnCN¥102.40bnCN¥101.02bn
Cash and short-term investments———CN¥18.15bnCN¥16.95bnCN¥17.16bnCN¥18.36bnCN¥16.18bn
DebtCN¥2.20bnCN¥2.25bnCN¥1.64bnCN¥44.86bnCN¥13.13bnCN¥13.78bnCN¥10.95bnCN¥11.11bn
Shareholders' equityCN¥28.76bnCN¥29.28bnCN¥28.55bnCN¥28.25bnCN¥27.77bnCN¥28.23bnCN¥27.24bnCN¥26.43bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin7.8%7.7%8.0%7.7%8.0%8.9%
Operating margin2.5%2.6%2.0%2.0%2.9%3.9%
Net margin1.4%1.7%1.4%1.5%2.0%2.8%
Return on equity7.9%9.2%9.1%8.5%10.5%14.1%
Return on assets1.9%2.4%2.3%2.3%2.8%3.8%
Free cash flow yield19.6%16.3%23.7%19.8%18.1%18.7%
Revenue growth6.3%1.1%6.9%14.7%10.4%11.4%
Earnings growth-10.1%15.3%4.3%-14.8%-20.4%78.1%
Current ratio1.25x1.27x1.26x1.27x1.28x1.29x
Debt to equity0.06x0.40x0.52x0.58x0.64x0.72x
Equity ratio24.5%26.6%25.8%26.7%27.2%27.0%
Interest coverage3.99x2.94x2.29x2.18x2.92x3.84x
R&D as a share of sales0.1%0.1%0.1%0.1%0.2%0.1%
Buybacks as a share of market value1.0%-1.3%6.8%1.2%-2.2%22.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.7%7.8%12.5%
Operating income12.3%-1.5%16.7%
Net income2.6%-6.0%12.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin7.8%7.8%8.0%8.1%
Operating margin2.5%2.3%2.6%2.7%
Net margin1.5%1.5%1.7%1.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings11.510.412.612.512.211.721.121.124.337.7
Price to sales0.20.20.20.20.20.30.40.30.50.5

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 8 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2019FY2018
Paid in the year0.200.200.250.2770.1120.1860.0370.037
  • 1.29-for-1 split · 7 Jun 2024
  • 7-for-5 split · 12 Oct 2023
  • 1.49-for-1 split · 29 Jun 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.